The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Open accessAbstract
Phase 3 trial of seladelpar in PBC with inadequate response or unacceptable side effects with UDCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, seladelpar was well tolerated.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“As detailed earlier, pruritus was less frequent in seladelpar when compared to placebo.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“There were no reported treatment-related deaths [16,23,47].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“However, ALT and GGT were significantly decreased with seladelpar which indicates reduced hepatocellular injury [47].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“Those on seladelpar 10 mg (n = 49) achieved −3.2 points while patients on placebo (n = 23) achieved −1.7 points (p = 0.005).”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationInterleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S. R., Haugen, H. S., Maurer, M., Harder, B., Johnston, J., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,015
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationAlternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., & Chawla, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.003 · Cited by 847
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationThe 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Self-citationCorpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Self-citation
Cited by
Items 201–277 of 277
Franke, A., Müller, T., Stein, K., Bantel, H., Günther, R., & Wiegand, J. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102254
Advances in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Sandhu, S., & Goel, A. (2026) · Seminars in Liver Disease · doi:10.1055/a-2952-2261
Elafibranor y seladelpar en colangitis biliar primaria
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/49.486.5
van de Graaf, S. F. J., Hirschfield, G. M., Trauner, M., Verkade, H. J., Takkenberg, R. B., Plichta, A., Lopez, C. L., Chiara, F. D., & Platenburg, G. J. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6634819
Self-citationRen, H., Ye, C., Li, T., Wang, D., Ou, S., & Peng, Y. (2026) · Talanta Open · doi:10.1016/j.talo.2026.100680
Efficacy, symptoms, and safety of second-line PBC therapies: a network meta-analysis
Zhao, W., Wu, Z., Kou, Q., Qiao, S., Liu, Z., & Zhang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1859342
Hogerty, C., Zhao, Y., Wang, W., Weinman, S. A., & Zhong, W. (2026) · Biomolecules · doi:10.3390/biom16060895
Nouvelles pistes thérapeutiques pour le traitement de la cholangite biliaire primitive
Brice, C., & Louvet, A. (2025) · médecine/sciences · doi:10.1051/medsci/2025109
Pediatric Cholestatic Liver Disease: A Contemporary Review of Etiology, Diagnostics, and Management
Vather, M., Lee, J., & Vittorio, J. (2026) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-026-00386-4
Gish, R. G., Mendler, M. H., Mena, E., Kim, C., Perez, C. F. M., Pan, Y., Do, L., Samnaliev, M., & Agapova, M. (2026) · Liver international communications. · doi:10.1002/lci2.70044
Kumar, S., Shamseddine, N., Yang, H., Zhang, S., Chen, J., & Kowdley, K. V. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0179
Self-citationHishiki, T., Honda, A., Tanaka, R., Minomo, Y., Minamisawa, O., Konno, T., Kamata, S., Kamichatani, W., Tokuoka, S. M., Kita, Y., et al. (2026) · Biomolecules · doi:10.3390/biom16081078
Sanai, F. M., Alghamdi, A. S., Khathlan, A. A., Qutub, A. A., Quraishi, H. A., Alghamdi, M., ALZaabi, M. E. H., Mawardi, M., Altarrah, M. Y., Alnahdi, N., et al. (2026) · Cureus · doi:10.7759/cureus.113526
Nesbitt, G., & Curley, A. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261427491
Fan, Z., Jia, S., Wei, Y., Fan, X., Li, X., & Wang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845113
PPAR-Agonisten - etablierte Substanzen und neue Entwicklungen
Herta, T., & Tacke, F. (2025) · Gastro-News · doi:10.1007/s15036-025-3896-8
Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
Tatscher, E., Mady, S., & Fickert, P. (2025) · Seminars in Liver Disease · doi:10.1055/a-2601-9426 · Cited by 1
Overlap Syndromes and Associated Immunoglobulin-G4-Related Liver Diseases
Malakar, S., Kumar, S., Roy, A., Giri, S., Rungta, S., Agarwal, M., Singh, A., Bassi, N., Samanta, A., Ghoshal, U. C., et al. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103564
Bolis, F., & Carbone, M. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.003
Bergheim, I., Cadranel, J. F. D., Chen, J., Ding, W., Eferl, R., García‐Ruiz, C., Jaeschke, H., Kazerouni, F., Lonardo, A., Mann, D. A., et al. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005110
Crittenden, D. B., & Hirschfield, G. M. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70777
Self-citationDelphi consensus in primary biliary cholangitis: Collective introspection to set a path forward
Assis, D. N. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.07.010
Jayasekera, C. R., Barnhill, M. S., Chascsa, D. M. H., Croome, K. P., Carey, E. J., & Vargas, H. E. (2025) · Clinical Transplantation · doi:10.1111/ctr.70180
Guri, Y., & Kremer, A. E. (2024) · Schweizer Gastroenterologie · doi:10.1007/s43472-024-00132-x
Self-citationJain, R., Kaur, G., Grover, P., Yasin, Z., & Singh, B. (2026) · Livers · doi:10.3390/livers6040077
General Hepatology Concerns for the Patient with Cholestatic Liver Disease
Deeb, M., & Ma, M. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.007
A decade of progress in cholestatic liver diseases: navigating a new era
Ronca, V., Maria, B., & Lleò, A. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00045-2
Yamazaki, T., Yang, Y., Schöler, D., Yukawa‐Muto, Y., Kouno, T., Harberts, A., Sakane, S., Freund, L., Hsu, C. L., Whisenant, T. C., et al. (2025) · PPAR Research · doi:10.1155/ppar/2935230 · Cited by 2
Kuo, S. Z., Yin, J. H., & Loomba, R. S. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70435 · Cited by 2
Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States
Kumar, S., Shamseddine, N., Yang, H., Zhang, S., Ye, D., Seshasayee, S. M., Chen, J., & Kowdley, K. V. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03439-6
Self-citationKemp, R., Kean, T. J., & Medvedev, K. E. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00936-w
Beres, R. L., Setchell, K. D. R., Mouzaki, M., & Zhao, X. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16070391
Seladelpar As a PPAR-δ Agonist in PBC: Pharmacological Insights and Clinical Applications
Lourdu, V., & Gayatri Devi, S. (2026) · Oriental Journal Of Chemistry · doi:10.13005/ojc/420108
Pharmacology of pruritus (pathophysiology, therapeutic targets)
Brenaut, E., & Misery, L. (2026) · Therapies · doi:10.1016/j.therap.2026.06.001
Qualitative Evaluation of Fatigue and Pruritus Among Patients with Primary Biliary Cholangitis
Levy, C., Williams, B., Sowell, F. G., Dietrich, J., Boing, E., Wright, G., & Schattenberg, J. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03691-4 · Cited by 1
Self-citationNeue Standards in der Behandlung der primären biliären Cholangitis
Vögelin, M., & Kremer, A. E. (2025) · Schweizer Gastroenterologie · doi:10.1007/s43472-025-00173-w
Self-citationDüll, M. M., & Kremer, A. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34172-4.00031-8
Self-citationKommentar zu: Primär biliäre Cholangitis: Elafibranor durchläuft erfolgreich Phase-III-Prüfung
Sebode, M. (2024) · Gastroenterologie up2date · doi:10.1055/a-2410-4314
AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update
Aghemo, A., Calvaruso, V., Carbone, M., Cazzagon, N., Cristoferi, L., D’Amato, D., D’Ambrosio, R., Fianchi, F., Germani, G., Giannini, E. G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.06.019 · Cited by 3
Self-citationMASLD In PBC : A Shift From Liver‐Centred to Cardiometabolic Risk Assessment?
Colapietro, F., & Viganò, M. (2026) · Liver International · doi:10.1111/liv.70817
Primary biliary cholangitis, a rising health burden
Elnaggar, M., Elkhattib, I., Abomhya, A., & Boyer, J. L. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00165 · Cited by 1
Shamseddine, N., Yang, H., Zhang, S., Ye, D., Seshasayee, S. M., Chen, J., Kumar, S. R., & Kowdley, K. V. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0172
Self-citationRen, W., Zhang, C., Wang, H., Song, H., Zhu, X., Zhang, Z., Zhao, S., & Wang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1674693
Romero‐Cristóbal, M. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2026.502720
Immunomodulatory mechanisms of bile acids in autoimmune diseases along the gut-liver axis
Zhang, S., Xiong, X., Wei, S., Meng, R., An, H., & Chen, L. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104183 · Cited by 1
Qasim, B., Kumari, H., Kashif, S. N., Abbas, S. M. I., Hani, O., Salma, O., Sauleh, A., Adnan, F., Ali, M., Raheem, A., et al. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00464-6
Thakkar, H. H., Mathew, N. V., Reddy, E. P., Cheetiyar, A. L., Kommalapati, V., Mathew, A., Rajendiran, A., Riyaz, R., Joseph, N., Obadi, A. H., et al. (2025) · Cureus · doi:10.7759/cureus.82008 · Cited by 3
He, Y., He, H., Qi, L., & Xie, Y. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0239
10. Advances in the Management of Intractable Hepato-biliary Diseases
Tanaka, A. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1748
Berg, T., Trauner, M., & Trivedi, P. J. (2025) · EMJ Hepatology · doi:10.33590/emjhepatol/tnom7344
Gish, R. G., Mendler, M. H., Mena, E., Kim, C., Perez, C., Pan, Y., Samnaliev, M., Ito, D., & Agapova, M. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2595885
Berikkhanov, Z. G. M., Akulov, Z. A., Emtsev, M. A., Tarabrin, E. А., Shestakov, A., Kotelnikov, A., Nikolaev, A., Razumovsky, V. S., Ivanova, M. Y., Ebrahimnezhad, M., et al. (2026) · Metabolites · doi:10.3390/metabo16100721
Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective
Bowlus, C. L., Bittencourt, P. L., Bobat, B., Gulamhusein, A. F., Kowdley, K. V., Levy, C., Lleo, A., Ma, X., & Tanaka, A. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004054 · Cited by 2
Self-citationNew therapies for primary biliary cholangitis
Sohal, A., Alamgir, M., & Kowdley, K. V. (2026) · Hepatology International · doi:10.1007/s12072-026-11088-2
Self-citationRomero‐Cristóbal, M. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502720
New therapies for primary biliary cholangitis usher in a personalised approach to treatment
France, N. L. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01129-x
Fernández‐Rodríguez, C., García, M. L. G., & Olveira, A. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18048
American Association for the Study of Liver Diseases, & EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (2026) · Hepatology · doi:10.1097/hep.0000000000001791
Khamis, F., Teoh, E.-S., & Chan, W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-184
Choi, Y., Schwab, A. J., Lim, J., Carlisle, S. M., McWherter, C. A., & Johnson, J. D. (2026) · PPAR Research · doi:10.1155/ppar/2362528
Self-citationSystemischer Pruritus: hämatologische, nephrogene und hepatobiliäre Ursachen im Fokus
Koschmieder, S., Brand, M., & Kremer, A. E. (2026) · Die Dermatologie · doi:10.1007/s00105-026-05722-1
Self-citationZhou, H., Yang, J., Wu, W., Wei, S., ZHAO, Y., & Li, C. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2695704
Silveira, I. B., Moraes, B. D. F., Rezende, R. A. A., & Cançado, G. G. L. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003108
BAKULIN, I., & Mirtskhulava, V. V. (2026) · Медицинский вестник МВД · doi:10.52341/20738080_2026_143_4_28
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Álvares‐da‐Silva, M. R., Andreoné, P., Arrese, M. A., Corpechot, C., Elbeshbeshy, H. A., Francque, S., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.016 · Cited by 1
Self-citationAustrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis
Halilbasic, E., Tatscher, E., Aigner, E., Burghart, L., Graziadei, I. W., Hametner‐Schreil, S., Hofer, B., Hofer, H., Maieron, A., Mandorfer, M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02798-6
Nguyen, H. H., & Swain, M. G. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70659
Can we cure primary biliary cholangitis?
Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102786
Self-citationYounossi, Z. M., Papatheodoridis, G., Tsochatzis, E. A., Buti, M., Rimassa, L., Pinzani, M., Lleò, A., Shawcross, D. L., Tacke, F., Wong, V. W., et al. (2026) · Liver International · doi:10.1111/liv.70806 · Cited by 1
Self-citationRomeo, M., Basile, C., Imperatore, A., Mozzi, G., Nardo, F. D., Napolitano, C., Vaia, P., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2026) · Cells · doi:10.3390/cells15141292 · Cited by 2
Faria, H. S., Sobral, M. V. S., Soares, V. G., Cavalheiro, T. T., Nishimoto, B., Pirolla, R. D. C., Sampaio, A. P., Gonçalves, O. R., COSTA, D. G. D., & Souto, E. B. (2024) · Research Square · doi:10.21203/rs.3.rs-4369688/v1
Metadata
- Authors
- Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., Zigmond, E., Jeong, S.-H., Yilmaz, Y., Kallis, Y., Corpechot, C., Buggisch, P., Invernizzi, P., Londoño Hurtado, M. C., Bergheanu, S., Yang, K., Choi, Y.-J., Crittenden, D. B., & McWherter, C. A.
- Affiliations
- University Health Network (CA)
- From the Toronto Centre for Liver Disease, Division of Gastroenterology and Hepatology, University Health Network, Toronto General Hospital, Toronto (G.M.H.); the Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento (C.L.B.), and CymaBay Therapeutics, Newark (K.Y., Y.-J.C., D.B.C., C.A.M.) — both in California; the University of Texas Southwestern Medical School, Dallas (M.J.M.), and the Departments of Medicine and Surgery, Baylor College of Medicine, Houston (J.M.V.) — both in Texas; the Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (A.E.K.); Liver Institute Northwest, Seattle (K.V.K.); the Division of Digestive Health and Liver Diseases, University of Miami, Miami (C.L.); the Liver Autoimmunity Unit, Hospital Italiano de Buenos Aires, Buenos Aires (A.V.); Centro de Investigación y Gastroenterología, Mexico City (A.L.L.G.C.); the Department of Basic Medical Sciences, Faculty of Publ...
- ORCID
- Hirschfield, Gideon M.
- Bowlus, Christopher L.
- Mayo, Marlyn J.
- Kremer, Andreas E.
- Vierling, John M.
- Kowdley, Kris V.
- Levy, Cynthia
- Villamil, Alejandra
- Janczewska, Ewa
- Zigmond, Ehud
- Jeong, Sook-Hyang
- Yilmaz, Yusuf
- Kallis, Yiannis
- Corpechot, Christophe
- Buggisch, Peter
- Invernizzi, Pietro
- Yang, Ke
- Choi, Yun-Jung
- Crittenden, Daria B.
- McWherter, Charles A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-29
- Volume
- 390
- Issue
- 9
- Pages
- 783-794
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4392015136
- Cited by
- 286
- References
- 42
- Citations by year
- 2026: 106 · 2025: 128 · 2024: 52
- FWCI
- 73.92
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- CymaBay Therapeutics
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- seladelpar, primary biliary cirrhosis, PPARδ agonist, ursodeoxycholic acid, biochemical response, alkaline phosphatase, pruritus
- MeSH terms
- Acetates, Administration, Oral, Alkaline Phosphatase, Bilirubin, Cholagogues and Choleretics, Double-Blind Method, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Pruritus, Ursodeoxycholic Acid, Treatment Outcome, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.